Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics, Inc. (symbol: ATXS) is a pioneering biopharmaceutical company dedicated to developing transformative treatments for rare and niche allergic and immunological diseases. With a mission to improve the lives of patients and families impacted by these conditions, Astria Therapeutics is at the forefront of innovative medical research and development.
The company’s lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein. This promising therapy is currently in preclinical development, targeting the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent and severe swelling. By inhibiting plasma kallikrein, STAR-0215 aims to prevent the debilitating effects of HAE, offering hope to patients worldwide.
Astria Therapeutics is also advancing another significant product candidate, STAR-0310. This monoclonal antibody OX40 antagonist is being developed to treat atopic dermatitis (AD), an immune disorder that causes chronic skin inflammation and intense itching. Currently in preclinical development, STAR-0310 targets the immune pathways involved in AD, potentially providing relief and improved quality of life for sufferers.
Recently, Astria Therapeutics has made significant strides in its research and development efforts. The company remains committed to advancing its pipeline and exploring strategic partnerships to bring these innovative therapies to market. Financially, Astria Therapeutics continues to focus on maintaining a strong balance sheet to support its ambitious research programs and clinical trials.
In addition to its core projects, Astria Therapeutics actively engages with the medical community, patient advocacy groups, and regulatory bodies to ensure its treatments meet the highest standards of efficacy and safety. By fostering these collaborations, the company aims to accelerate the delivery of breakthrough therapies to those in need.
For the latest updates on Astria Therapeutics, including news on their clinical trials, partnerships, and corporate developments, stay tuned to StockTitan.
Astria Therapeutics (NASDAQ:ATXS) has chosen Ypsomed as its partner to develop an autoinjector for STAR-0215, a therapy for Hereditary Angioedema (HAE). The collaboration aims to support Astria's goal of offering patients a choice between infrequent three- and six-month administration options. Astria plans to launch STAR-0215 with both the Ypsomed YpsoMate autoinjector and a pre-filled syringe, pending regulatory approval. The autoinjector is considered ideal for STAR-0215 due to its ease of use, needle shielding feature, and quick injection with low risk of pain. This partnership aligns with Astria's vision of providing effective HAE attack protection while minimizing treatment burden.
Astria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company specializing in allergic and immunological diseases, has announced its participation in the 2024 Wedbush PacGrow Healthcare Conference in New York, NY. The company's CEO, Jill C. Milne, Ph.D., will be part of a panel discussion titled 'HAE Ya! The Changing Face of the HAE Therapeutic Landscape' on Wednesday, August 14 at 2:30pm ET.
This panel will focus on hereditary angioedema (HAE), a rare genetic disorder that causes severe swelling in various parts of the body. Astria's participation in this conference highlights its commitment to advancing therapies for HAE and other immunological conditions, potentially impacting its stock performance and investor interest in the biopharmaceutical sector.
Astria Therapeutics (Nasdaq: ATXS), a biopharmaceutical company focused on allergic and immunological diseases, has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The options, totaling 29,150 shares of common stock, were awarded on August 1, 2024, with an exercise price of $11.19 per share, matching the closing price on the grant date.
These options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for inducement awards to new employees.
Astria Therapeutics (Nasdaq: ATXS) announced the grant of stock options for 123,500 shares of its common stock on July 1, 2024, under its 2022 Inducement Stock Incentive Plan.
This grant, aimed at three new employees, aligns with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for their employment.
Each option has an exercise price of $9.25, equal to the closing price on the grant date, and will vest over four years.
25% of the shares will vest after the first year of employment, with the remainder vesting monthly over the next three years, contingent on continued employment.
Astria Therapeutics announced on June 3, 2024, that it has granted stock options to purchase 40,000 shares of common stock under its 2022 Inducement Stock Incentive Plan. These options were provided as an inducement to a new employee, with the exercise price set at $9.16, matching the closing price of the stock on the grant date. The vesting schedule spans four years: 25% on the first anniversary of the employee's start date and the remaining shares vesting monthly over the next 36 months. The grants comply with Nasdaq Listing Rule 5635(c)(4).
Astria Therapeutics (NASDAQ: ATXS), a biopharmaceutical company specializing in therapies for allergic and immunological conditions, announced that CEO Jill C. Milne, Ph.D., will participate in a fireside chat at the Jefferies Healthcare Conference. The event is scheduled for June 6th at 10:00am ET in New York, NY. A webcast of the presentation will be available live and as an archived replay for 30 days on the company's investor relations website.
Astria Therapeutics (NASDAQ: ATXS) will present final Phase 1a data for STAR-0215 at the Eastern Allergy Conference in Palm Beach, Florida, on June 1, 2024. The focus will be on updated results for hereditary angioedema treatment. Jessica Best, VP of Medical Affairs, will present the poster at 9:45am EST.
Astria Therapeutics (NASDAQ: ATXS) will present two posters at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain, on June 1, 2024.
Dr. Marcus Maurer will present the ALPHA-SOLAR trial of STAR-0215 for treating hereditary angioedema (HAE), detailing its rationale and design.
Dr. Nikos Biris will present on the characterization of STAR-0310, a novel OX40 antagonistic monoclonal antibody.
Both sessions will take place on June 1 at 12:00pm CEST.
Astria Therapeutics, Inc. (NASDAQ:ATXS) reported financial results for Q1 2024, highlighting the positive proof-of-concept results of STAR-0215 for HAE treatment. The company plans to start Phase 3 trials in Q1 2025 and expand label with Q6M administration. Moreover, Astria is developing STAR-0310 for atopic dermatitis and aims to submit an IND application by 2024. The company also shared corporate updates and financial results.
Astria Therapeutics, a biopharmaceutical company, will be presenting information on STAR-0310 at the Society for Investigative Dermatology Annual Meeting. The presentation will focus on the preclinical profile of a novel OX40 antagonistic monoclonal antibody. Dr. Chunxia Lily Zhao will present the poster at the event in May 2024.
FAQ
What is the current stock price of Astria Therapeutics (ATXS)?
What is the market cap of Astria Therapeutics (ATXS)?
What does Astria Therapeutics, Inc. specialize in?
What is STAR-0215?
What is hereditary angioedema (HAE)?
What is STAR-0310?
What is atopic dermatitis (AD)?
How is Astria Therapeutics funded?
Does Astria Therapeutics collaborate with other organizations?
How can I stay updated on Astria Therapeutics' latest developments?
What is the significance of STAR-0215 in treating HAE?
What are the benefits of STAR-0310 for atopic dermatitis patients?
